theophyllamine

Theophyllamine is a methylxanthine-related small molecule described in older literature as a distinct compound investigated for effects on dopaminergic responsiveness, including potentiation of central dopamine stimulation in preclinical studies. In a small clinical Parkinsonism study, theophyllamine reportedly did not improve symptoms in patients already receiving levodopa. The available context also indicates historical confusion or conflation with aminophylline, but for this annotation theophyllamine is treated as the exact queried entity rather than aminophylline. No clear evidence from the provided material supports modern commercial development, regulatory approval, or an identified contemporary sponsor for theophyllamine.

Other names

theophyllamine